Literature DB >> 31632772

Optimal postoperative surveillance strategy in patients undergoing neoadjuvant chemoradiotherapy followed by surgery for esophageal carcinoma.

Kotaro Sugawara1, Hiroharu Yamashita1, Yasuyuki Seto1.   

Abstract

Entities:  

Year:  2019        PMID： 31632772      PMCID： PMC6783738          DOI： 10.21037/jtd.2019.08.89

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

1.  Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing.

Authors:  Emmanuele Abate; Steven R DeMeester; Joerg Zehetner; Arzu Oezcelik; Shahin Ayazi; Jesse Costales; Farzaneh Banki; John C Lipham; Jeffrey A Hagen; Tom R DeMeester
Journal:  J Am Coll Surg       Date:  2010-04       Impact factor: 6.113

2.  A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer.

Authors:  D Vallböhmer; Arnulf H Hölscher; S DeMeester; T DeMeester; J Salo; J Peters; T Lerut; S G Swisher; W Schröder; E Bollschweiler; W Hofstetter
Journal:  Ann Surg       Date:  2010-11       Impact factor: 12.969

3.  Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation.

Authors:  Lucian R Chirieac; Stephen G Swisher; Jaffer A Ajani; Ritsuko R Komaki; Arlene M Correa; Jeffrey S Morris; Jack A Roth; Asif Rashid; Stanley R Hamilton; Tsung-Teh Wu
Journal:  Cancer       Date:  2005-04-01       Impact factor: 6.860

4.  Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.

Authors:  Mian Xi; Christopher L Hallemeier; Kenneth W Merrell; Zhongxing Liao; Mariela A Blum Murphy; Linus Ho; Wayne L Hofstetter; Reza Mehran; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Dipen M Maru; Ritsuko Komaki; Jaffer A Ajani; Steven H Lin
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

5.  Esophageal and esophagogastric junction cancers, version 1.2015.

Authors:  Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Stephen Besh; Joseph Chao; Prajnan Das; Crystal Denlinger; Paul Fanta; Charles S Fuchs; Hans Gerdes; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kory Jasperson; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; A Craig Lockhart; Mary F Mulcahy; Mark B Orringer; James A Posey; George A Poultsides; Aaron R Sasson; Walter J Scott; Vivian E Strong; Thomas K Varghese; Mary Kay Washington; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-02       Impact factor: 11.908

6.  Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.

Authors:  Julie Vincent; Christophe Mariette; Denis Pezet; Emmanuel Huet; Franck Bonnetain; Olivier Bouché; Thierry Conroy; Bernard Roullet; Jean-François Seitz; Jean-Philippe Herr; Frédéric Di Fiore; Jean-Louis Jouve; Laurent Bedenne
Journal:  Eur J Cancer       Date:  2015-07-07       Impact factor: 9.162

7.  Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.

Authors:  Bryan M Burt; Shawn S Groth; Yvonne H Sada; Farhood Farjah; Lorraine Cornwell; David J Sugarbaker; Nader N Massarweh
Journal:  Ann Surg       Date:  2017-08       Impact factor: 12.969

8.  Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.

Authors:  Yin-Kai Chao; Sheng-Chieh Chan; Yun-Hen Liu; Huan-Wu Chen; Yung-Liang Wan; Hsien-Kun Chang; Kang-Hsing Fan; Hui-Ping Liu
Journal:  Ann Surg       Date:  2009-03       Impact factor: 12.969

9.  Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.

Authors:  P van Hagen; B P L Wijnhoven; P Nafteux; J Moons; K Haustermans; G De Hertogh; J J B van Lanschot; T Lerut
Journal:  Br J Surg       Date:  2012-11-23       Impact factor: 6.939

10.  Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.

Authors:  F Noble; M A Lloyd; R Turkington; E Griffiths; M O'Donovan; J R O'Neill; S Mercer; S L Parsons; R C Fitzgerald; T J Underwood
Journal:  Br J Surg       Date:  2017-09-25       Impact factor: 6.939
View more
  1 in total

1.  Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy.

Authors:  Roberta La Mendola; Maria Bencivenga; Lorena Torroni; Luca Alberti; Michele Sacco; Francesco Casella; Cecilia Ridolfi; Nicola Simoni; Renato Micera; Michele Pavarana; Giuseppe Verlato; Simone Giacopuzzi
Journal:  Ann Surg Oncol       Date:  2020-10-19       Impact factor: 5.344
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.